Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy

Administration of the anti-PD-1 antibody nivolumab to patients with non-small cell lung cancer results in sustained binding (for about 20 weeks) of nivolumab to PD-1 on lymphocytes Thus, it is also expected that programmed death-ligand 1 (PD-L1) antibody binding to PD-L1 on cancer cells is sustainable. This suggests that administration of a molecular-targeted agent that inhibits vascular endothelial growth factor (VEGF) as a subsequent therapy for patients with progressive disease treat-